A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

Clinical trial NCT07742527 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07742527
Sponsor: GlaxoSmithKline
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2026-10-16
Primary completion: 2027-08-05
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.